Clinical Trial: Clinical Study on Feasibility, Efficacy and Safety of Short Term Induced Redifferentiation with Zurletrectinib to Promote Iodine Uptake in NTRK Fusion Positive Radioiodine Refractory Differentiated Thyroid Cancer (RAIR-DTC) (China)

China, Oct. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical Study on Feasibility, Efficacy and Safety of Short Term Induced Redifferentiation with Zurletrectinib to Promote Iodine Uptake in NTRK Fusion Positive Radioiodine Refractory Differentiated Thyroid Cancer (RAIR-DTC)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133671

Registration Time: 2026/09/30

Type: Interventional study

Primary Sponsor: Peking Union Medical College Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341213

Published by HT Digital Content Services with permission from Health Daily Digest....